Alps Advisors Inc. trimmed its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) by 42.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 88,224 shares of the biopharmaceutical company's stock after selling 64,538 shares during the quarter. Alps Advisors Inc. owned approximately 0.06% of Arbutus Biopharma worth $239,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in Arbutus Biopharma by 8.9% in the second quarter. JPMorgan Chase & Co. now owns 64,191 shares of the biopharmaceutical company's stock worth $173,000 after purchasing an additional 5,265 shares during the last quarter. SG Americas Securities LLC grew its holdings in Arbutus Biopharma by 62.5% in the second quarter. SG Americas Securities LLC now owns 21,518 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 8,274 shares during the last quarter. Front Row Advisors LLC purchased a new position in Arbutus Biopharma in the first quarter worth $31,000. Principal Financial Group Inc. purchased a new position in Arbutus Biopharma in the second quarter worth $32,000. Finally, WMG Financial Advisors LLC purchased a new position in Arbutus Biopharma in the second quarter worth $34,000. 29.63% of the stock is owned by hedge funds and other institutional investors.
Get Arbutus Biopharma alerts:Analyst Ratings Changes
Several equities analysts have issued reports on ABUS shares. HC Wainwright cut their price target on shares of Arbutus Biopharma from $7.50 to $6.00 and set a "buy" rating on the stock in a report on Thursday, November 10th. StockNews.com started coverage on shares of Arbutus Biopharma in a report on Wednesday, October 12th. They issued a "hold" rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.50.
Arbutus Biopharma Price Performance
Shares of ABUS opened at $2.70 on Thursday. Arbutus Biopharma Co. has a 1-year low of $1.85 and a 1-year high of $6.50. The company's fifty day moving average price is $2.25 and its 200-day moving average price is $2.39.Arbutus Biopharma Company Profile
(Get Rating)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
Read More
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.